Pesquisar
Prothena Corporation PLC
PRTAAdicionar à lista de desejos
8.320USD
-0.360-4.15%
Fechamento 09-24 16:00（ET）
435.55MValor de mercado
PerdaP/L TTM
Sobre o Prothena Corporation PLC Empresa
Prothena Corporation plc is an Ireland-based late-stage clinical biotechnology company. The Company is engaged in protein dysregulation and a pipeline of investigational therapeutics for rare peripheral amyloid diseases. The Company is advancing a pipeline of therapeutic candidates for a range of indications and targets to integrate scientific insights around neurological dysfunction and the biology of misfolded proteins. The Company’s pipeline includes both wholly owned and partnered programs being developed for the potential treatment of diseases, including AL amyloidosis, ATTR amyloidosis, Alzheimer’s disease, Parkinson’s disease and a range of other neurodegenerative diseases. Its clinical programs include birtamimab for the potential treatment of AL amyloidosis, prasinezumab for the potential treatment of Parkinson’s disease, NNC6019/PRX004 for the potential treatment of ATTR amyloidosis, and PRX005 and PRX012 for the potential treatment of Alzheimer’s disease.
Prothena Corporation PLC Perfil
Código da empresaPRTA
Nome da EmpresaProthena Corporation PLC
Data de listagemDec 21, 2012
CEOKinney (Gene G)
Número de funcionários163
Tipo de títulosOrdinary Share
Fim do ano fiscalDec 21
Endereço77 Sir John Rogerson's Quay, Block C
CidadeDUBLIN
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísIreland
Código postalD02 VK60
Telefone35312362500
Sitehttps://www.prothena.com/
Código da empresaPRTA
Data de listagemDec 21, 2012
CEOKinney (Gene G)
Executivos da empresa Prothena Corporation PLC
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Brandon S. Smith
Mr. Brandon S. Smith
Chief Operating Officer
Chief Operating Officer
130.00K
--
Mr. Brandon S. Smith
Mr. Brandon S. Smith
Chief Operating Officer
Chief Operating Officer
130.00K
--
Mr. Brandon S. Smith
Mr. Brandon S. Smith
Chief Operating Officer
Chief Operating Officer
130.00K
--
Dr. Wagner M. Zago, Ph.D.
Dr. Wagner M. Zago, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
85.00K
--
Dr. Wagner M. Zago, Ph.D.
Dr. Wagner M. Zago, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
85.00K
--
Dr. Wagner M. Zago, Ph.D.
Dr. Wagner M. Zago, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
85.00K
--
Mr. Michael Isaacs
Mr. Michael Isaacs
General Counsel, Corporate Secretary
General Counsel, Corporate Secretary
35.74K
-36.59%
Mr. Michael Isaacs
Mr. Michael Isaacs
General Counsel, Corporate Secretary
General Counsel, Corporate Secretary
35.74K
-36.59%
Mr. Michael Isaacs
Mr. Michael Isaacs
General Counsel, Corporate Secretary
General Counsel, Corporate Secretary
35.74K
-36.59%
Dr. Dennis J. Selkoe, M.D.
Dr. Dennis J. Selkoe, M.D.
Independent Director
Independent Director
4.21K
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Brandon S. Smith
Mr. Brandon S. Smith
Chief Operating Officer
Chief Operating Officer
130.00K
--
Mr. Brandon S. Smith
Mr. Brandon S. Smith
Chief Operating Officer
Chief Operating Officer
130.00K
--
Mr. Brandon S. Smith
Mr. Brandon S. Smith
Chief Operating Officer
Chief Operating Officer
130.00K
--
Dr. Wagner M. Zago, Ph.D.
Dr. Wagner M. Zago, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
85.00K
--
Dr. Wagner M. Zago, Ph.D.
Dr. Wagner M. Zago, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
85.00K
--
Dr. Wagner M. Zago, Ph.D.
Dr. Wagner M. Zago, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
85.00K
--
Perguntas frequentes
Quem são os cinco principais acionistas de Prothena Corporation PLC?
Os cinco principais acionistas de Prothena Corporation PLC são: Mr. Brandon S. Smith
Quantas instituições possuem ações da Prothena Corporation PLC (PRTA)?
Em 2026Q1, 436 instituições possuíam ações da Prothena Corporation PLC, com valor de mercado aproximado de 50.39M, representando 96.24% do total de ações. Em comparação com 2025Q4, a participação institucional aumentou em -14521914.00.